GeneMatrix Inc. (KOSDAQ:109820)
South Korea · Delayed Price · Currency is KRW 1,590.00
-5.00 (-0.31%)
At close: Sep 18, 2026
GeneMatrix Revenue
GeneMatrix had revenue of 1.14B KRW in the quarter ending September 30, 2019, a decrease of -5.39%. This brings the company's revenue in the last twelve months to 4.72B, down -3.67% year-over-year. In the year 2018, GeneMatrix had annual revenue of 4.73B, down -8.75%.
Revenue (ttm)
4.72B
Revenue Growth
-3.67%
P/S Ratio
6.89
Revenue / Employee
152.32M
Employees
31
Market Cap
32.53B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2018 | 4.73B | -454.26M | -8.75% |
| Dec 31, 2017 | 5.19B | 109.29M | 2.15% |
| Dec 31, 2016 | 5.08B | -235.40M | -4.43% |
| Dec 31, 2015 | 5.32B | -1.36B | -20.39% |
| Dec 31, 2014 | 6.68B | -614.29M | -8.43% |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2011 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2010 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2009 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GC Medical Science | 102.16B |
| Seoulin Bioscience | 83.17B |
| Cytogen | 27.38B |
| Dx & Vx | 26.22B |
| Protia | 17.75B |
| HLB Panagene | 14.71B |
| 3billion | 11.71B |
| GENINUS | 11.28B |